LON:MXCT - MaxCyte Stock Price, News & Analysis

GBX 122
0.00 (0.00 %)
(As of 09/18/2019 02:55 AM ET)
Today's Range
Now: GBX 122
50-Day Range
MA: GBX 121.91
52-Week Range
Now: GBX 122
Volume4,088 shs
Average Volume1,951 shs
Market Capitalization£69.90 million
P/E RatioN/A
Dividend YieldN/A
MaxCyte, Inc operates as a cell-based medicines and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. Read More…

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual Sales£16.67 million
Cash FlowGBX 28.10 per share
Book ValueGBX 23.90 per share



Market Cap£69.90 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MXCT News and Ratings via Email

Sign-up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

MaxCyte (LON:MXCT) Frequently Asked Questions

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

Has MaxCyte been receiving favorable news coverage?

Headlines about MXCT stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MaxCyte earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for MaxCyte.

Who are some of MaxCyte's key competitors?

What other stocks do shareholders of MaxCyte own?

Who are MaxCyte's key executives?

MaxCyte's management team includes the folowing people:
  • Mr. Douglas Arthur Doerfler, Co-Founder, CEO, Pres & Exec. Director (Age 63)
  • Mr. Ronald Evan Holtz, CFO, Sec. & Director (Age 61)
  • Mr. Maher Masoud, VP of Legal
  • Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 58)
  • Mr. Markus J. Hunkeler, VP of Marketing

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 122.

How big of a company is MaxCyte?

MaxCyte has a market capitalization of £69.90 million and generates £16.67 million in revenue each year. View Additional Information About MaxCyte.

What is MaxCyte's official website?

The official website for MaxCyte is http://www.maxcyte.com/.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.

MarketBeat Community Rating for MaxCyte (LON MXCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote "Outperform" if you believe MXCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel